Johnson & Johnson Reaffirms FY22 Outlook; Authorizes Up To $5 Bln Share Buyback
(RTTNews) - Johnson & Johnson (JNJ) On Wednesday reaffirmed its full-year 2022 guidance for earnings in the range of $10.65 to $10.75 per share and adjusted operational sales growth of 6.5 to 7.5 percent.
On average, 17 analysts polled by Thomson Reuters expect the company to report earnings of $10.07 per share on revenue growth of 1.5 percent to $95.14 billion for the year. Analysts' estimates typically exclude special items.
The company also announced that the Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock.
The company said repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions. Any shares acquired will be available for general corporate purpose.
read more
Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast
Johnson & Johnson reported Wednesday weak profit in its second quarter on charges, while adjusted earnings beat market estimates on sales growth. The drug major further trimmed its fiscal 2024 adjusted earnings outlook, but lifted operational sales view to mainly reflect the acquisition of Shockwave Medical. In pre-market activity on the NYSE, Johnson & Johnson shares were losing around 0.5...
RTTNews
|
105天前
Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26
Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.25 billion.
RTTNews
|
155天前
J&J Seeks EMA Approval For DARZALEX Quadruplet Therapy For Multiple Myeloma
Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced Wednesday the submission of a Type II variation application to the European Medicines Agency (EMA).
RTTNews
|
238天前
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial
Swiss biopharmaceutical company AC Immune SA (ACIU) announced Friday that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.
RTTNews
|
320天前
Integra LifeSciences To Acquire Acclarent For $275 Mln Cash
Medical technology firm Integra LifeSciences Holdings Corp. (IART) announced Wednesday that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing. This is subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.
RTTNews
|
322天前
Johnson & Johnson Guides FY24 Adj. EPS Below Estimates
Ahead of the meeting with the investment community at the New York Stock Exchange later on Tuesday, Johnson & Johnson (JNJ) initiated financial guidance for the full-year 2024 and for the long term.
RTTNews
|
330天前
Johnson & Johnson Trims FY23 Earnings, Net Sales Outlook
Healthcare company Johnson & Johnson (JNJ) on Wednesday updated its first-half financials and fiscal 2023 guidance which reflect its continuing operations as a company focused on transformational innovation in Pharmaceutical and MedTech, following the separation of Kenvue Inc., formerly Johnson & Johnson's Consumer Health business.
RTTNews
|
427天前
Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits
A U.S. appeals court has rejected Johnson & Johnson's bankruptcy move, saying that it can't escape from nearly 40,000 lawsuits filed by women who claimed to have developed ovarian cancer after using its asbestos contained talcum powder products. J&J, which already withdrew its talc-based baby powder, is now required to defend itself against these thousands of ovarian cancer claims.
RTTNews
|
638天前
